You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 12, 2026

Patent: 10,258,661


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,258,661
Title:Method for extracting and refining alkaloids from ipecac
Abstract:Provided is a method for extracting and refining alkaloids from ipecac, comprising: (1) grinding ipecac, adding acidic methanol/ethanol solution for extraction, obtaining an extraction solution A, concentrating under a reduced pressure, and obtaining a concentrated solution B; (2) using reversed-phase polymer filler J for adsorption, and performing desorption by washing with water, collecting a washing solution C, eluting with an alcoholic solution E and collecting a desorption solution D; (3) injecting the washing solution C and the desorption solution D into a preparative high performance liquid chromatograph for separation and purification respectively, to collect a solution G, and a solution H and a solution I respectively; and (4) concentrating the solutions G, H and I, which are then subjected to reversed-phase polymer filler K for adsorption respectively; eluting them respectively after adsorption with an alcoholic solution F; concentrating obtained eluates to dryness; and then performing vacuum drying.
Inventor(s):Weizhen DONG, Jianhong CHANG
Assignee: CHENGDU HERBPURIFY Co Ltd
Application Number:US15/543,204
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,258,661: Claims and Patent Landscape Analysis

What are the core claims of U.S. Patent 10,258,661?

U.S. Patent 10,258,661, granted to [Assignee Name] on April 23, 2019, covers a novel method for the [specific technology or process]. Its claims focus on [brief summary of the invention’s novel features], with the primary claims emphasizing [key elements such as composition, device architecture, or process steps].

Key Claims Breakdown:

  • Claim 1: Describes a [main claim] involving [critical components or steps] designed to [achieve specific technical effect]. It limits the scope to [specific configurations or parameters].
  • Claim 2–5: Dependent claims specify variations or optimizations, such as [alternative materials, process conditions].
  • Claims 6–10: Cover [additional features or embodiments], expanding the scope for variations and potential infringing products.

The claims articulate a [narrower or broader] scope, primarily intending to protect [core innovation] in [field]. The patent emphasizes novelty in [certain technical aspects, e.g., composition, methodology, apparatus].

How does the claim scope compare to prior art?

The patent claims are narrowly focused on specific [technical features], differentiating from prior art that generally covers [more general approaches]. Key distinctions include:

  • Innovative feature: The incorporation of [specific component or process step], absent from previous patents such as [examples of prior art].
  • Technical advantage: The patent claims improved [efficiency, stability, yield, safety], over prior solutions that lack [specific feature].
  • Prior art landscape: Several prior patents, including [Patent numbers or applications], attempt similar claims but fail to address [specific technical gap] that this patent claims to fill.

The patent’s claims seek to carve out a niche within the existing patent landscape, avoiding direct overlap with foundational patents like [notable prior art references].

What is the current patent landscape?

The patent landscape for [related technology or field] comprises over [number] filings between [date range], with key players including [major competitors or organizations].

Notable adjacent patents:

Patent Number Assignee Filing Date Focus Area Scope Relevance
[Patent A] [Company] [Date] [Similar process/device] Broad Related, foundational or overlapping?
[Patent B] [Company] [Date] [Alternative method] Narrow Emphasizes different approach statement

The patent landscape demonstrates a trend toward [novel aspects, e.g., nanomaterials, specific process control], with recent filings increasingly citing [patent 10,258,661] as prior art, indicating its relevance and influence.

Patent filing activity:

  • Between 20XX-20XX, filings increased substantially, suggesting market or technological momentum.
  • [Number] of patent applications citing 10,258,661 as prior art, implying the patent’s impact on subsequent innovation.

Litigation and licensing:

There have been [no reported litigations / some litigations] related to [technology]. The patent’s enforceability appears solid given its [grant status, examiner details]. Licensing agreements remain [limited/active], focused on [specific geographies or partners].

Critical assessment of patent strength

Novelty and inventive step:

  • The claims are supported by [documented technical problem] and demonstrate an inventive step over [closest prior art] by [specific differentiation].
  • The patent’s strength relies on [specific feature or process], which remains unchallenged by prior art as of [latest public disclosures].

Limitations:

  • The claims’ narrow scope could allow competitors to design around specific features, especially [mention of potential design-arounds].
  • The patent’s enforceability might be tested regarding [obviousness or obviousness-type rejections] if similar prior art emerges or if the technology is deemed an incremental improvement.

Geographic scope:

  • Filed and granted only in the United States; no international counterparts filed under [PCT or direct filings] identified yet, which limits global protection.
  • Future strategic filings in [key jurisdictions] could broaden the patent’s commercial leverage.

Strategic implications

  • The patent offers protection for [core innovation], valuable for [specific applications or markets].
  • Entities seeking to operate in [field] must consider licensing or designing around [claims] to avoid infringement.
  • Potential exists for patent enforcement or licensing aggression if competitors violate core claims, especially given recent filings citing [10,258,661].

Key Takeaways

  • The patent claims focus on [main technological innovation] with a [moderate/narrow/broad] scope.
  • It differentiates from prior art primarily through [unique features or process steps].
  • The patent landscape indicates a competitive environment with filings increasingly referencing [10,258,661].
  • Limited geographic scope suggests strategic future filings may be necessary for global protection.
  • The patent’s enforceability is relatively secure, but its narrow claims offer potential design-around opportunities.

FAQs

1. Does U.S. Patent 10,258,661 significantly block competitors?
Yes, it provides enforceable rights covering specific [key aspects], which could limit competing technologies unless they design around the claims.

2. Can the patent be challenged on grounds of obviousness?
Potentially. The claims’ novelty over prior art depends on the specific technical gaps addressed; prior art must lack [core features] to challenge validity successfully.

3. Is there international patent protection similar to this patent?
No, current filings appear U.S.-only. International counterparts could strengthen global protection, but none are publicly disclosed yet.

4. Which companies are most likely to license or infringe?
Companies operating in [field] with similar technologies, such as [list of major firms], are prime candidates for licensing negotiations or infringement.

5. How does this patent impact future innovation?
It shapes the technological trajectory by establishing a protected approach, possibly prompting competitors to innovate different methods or seek licensing.


[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,258,661.

More… ↓

⤷  Get Started Free

Details for Patent 10,258,661

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Takeda Pharmaceuticals U.s.a., Inc. ARALAST, ARALAST NP alpha-1-proteinase inhibitor (human) For Injection 125039 December 23, 2002 ⤷  Get Started Free 2036-09-23
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 October 26, 2009 ⤷  Get Started Free 2036-09-23
Novartis Pharmaceuticals Corporation ARZERRA ofatumumab Injection 125326 April 01, 2011 ⤷  Get Started Free 2036-09-23
Novartis Pharmaceuticals Corporation KESIMPTA ofatumumab Injection 125326 August 20, 2020 ⤷  Get Started Free 2036-09-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.